Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.

Trial Details

NCT ID
NCT05506332
Phase
PHASE1
Sponsor
University Hospital, Antwerp
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax
  • 6-mercaptopurine
Locations (sample)
  • Edegem, Antwerp, Belgium|51.15662,4.44504
  • Roeselare, West Vlaanderen, Belgium|50.94653,3.12269

Key Eligibility Criteria

  • Relapsed or refractory AML
  • Relapsed after or refractory to at least one cycle of intensive chemotherapy (combination of ara-c/anthracyclin) or four cycles of HMA (hypomethyla…
  • Adult AML aged \>/= 18 years
  • WHO performance status: grade 0-2 at the time of enrollment

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →